ReviewESMO gastrointestinal oncology2026
Transarterial chemoembolization (TACE) with or without immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Review in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is the standard of care for intermediate-stage unresectable hepatocellular carcinoma (HCC), but progression-free survival (PFS) with TACE alone remains limited. Recent randomized clinical trials have evaluated the addition of immune checkpoint inhibitors (ICIs) to TACE. We conducted a meta-analysis of randomized trials to assess the efficacy and safety of TACE plus ICIs versus TACE alone in unresectable HCC. Materials and methods: A systematic search of PubMed, Embase, Cochrane Library, and American Society of Clinical Oncology and European Society for Medical Oncology databases was carried out through 15 December 2025 and last updated on 3 June 2026 to identify randomized clinical trials comparing TACE with or without ICIs in unresectable HCC. Outcomes included PFS, objective response rate (ORR), overall survival (OS), and safety. Random-effects meta-analyses were conducted using R software (version 4.5.2, R Foundation for Statistical Computing, Vienna, Austria). Results: Six randomized clinical trials (EMERALD-1, EMERALD-3, Jia et al., LEAP-012, TALENTACE, and CARES-005) involving 2439 patients were included. Compared with TACE alone, combination therapy improved PFS [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.52-0.77, Conclusion: Adding ICIs to TACE improved PFS and response rates compared with TACE alone in unresectable HCC, at the cost of increased toxicity. OS benefit was borderline and should be interpreted with caution; longer follow-up is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.